BDH-Clinic Hessisch Oldendorf
Hessisch Oldendorf, 31840, Germany
Location status: Recruiting
NCT Number: NCT04449666
Neuropsychological and functional long-term consequences of subarachnoid hemorrhages (SAH) represent a great challenge, since sometimes considerable cognitive deficits occur without evidence of substantial brain damage. In this study, we want to examine if the frequently observed memory deficits are associated with hippocampal atrophy.
Interested in participating?
Request Info18 year–70 year
All sexes
Observational
Hessisch Oldendorf, 31840, Germany
Location status: Recruiting
Long-term or even permanent neuropsychological impairments are frequently observed after aneurysmal subarachnoid hemorrhages (aSAH). Among the most common impairments after aSAH are memory deficits. Volumetric MRI studies suggest an association of memory dysfunctions with temporal atrophy, especially of the hippocampus. In a previous study, 77 patients with good or moderate clinical outcome after aSAH were examined one year after discharge (Bendel et al., 2006). Temporomesial atrophy was detected without direct brain damage, e.g. by secondary ischemia. Due to the effects of complex cognitive impairments on the quality of life and participation in social and professional life, this relationship will be examined in more detail in the planned study. Specifically, we will investigate to what extent the frequently observed discrepancy between severe memory impairment and normal structural imaging results (no focal lesions in temporomesial areas) is due to hippocampal atrophy. In contrast to Bender and colleagues, this question will be investigated in the acute phase of the disease, immediately after admission to inpatient neurological rehabilitation.
Over a period of 24 months, 29 neurological rehabilitation patients with aSAH (Hunt & Hess grade I and II) are going to be included. Within the first week (day 1 to 7) after study enrollment, a native MRI examination (without contrast agent) is performed, in which a high-resolution 3D-MPRAGE sequence (T1 weighting) is measured in the sagittal plane. After checking the data quality of the 3D-MPRAGE sequence, especially with regard to its suitability for hippocampal volume determination, a comprehensive neuropsychological examination is performed, in which specific memory and attentional functions are tested.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Complex neuropsychological assessment testing attentional and memory functions. Additionally, a structural MRI is measured.
Time frame: 2 weeks
Hypothesis: patients have smaller hippocampal volume than healthy control subjects. For the hippocampal volume a structural MRI scan (3D-MPRAGE) is obtained
Time frame: 2 weeks
Hypothesis: patients have lower scores in the Visual and Verbal memory test (VVM) than healthy control subjects.
Time frame: 2 weeks
Hypothesis: hippocampal volumes differ between aSAH patients with surgical or endovascular treatment.
Time frame: 2 weeks
Hypothesis: there are no differences between ispi- and contralateral hippocampal volumes
Time frame: 2 weeks
Hypothesis: It is expected that there will be no difference in the ratings of hippocampal volume between two independent raters.
Time frame: 2 weeks
Hypothesis: patients have smaller intracranial volume than healthy control subjects.
Contact information is provided by the study sponsor or research team.
Melanie Boltzmann, PhD
CONTACT
Simone B Schmidt, PhD
CONTACT
BDH-Klinik Hessisch Oldendorf
Other
Investigation of the Relationship Between Hippocampal Volume and Memory Functions in in Patients With Aneurysmal Subarachnoid Hemorrhage (aSAH)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05432349
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Disease
Birmingham, Alabama, United States
View Trial DetailsNCT06617377
Cardiac Arrest, Cardiovascular Diseases
Toulouse, France
View Trial DetailsNCT07533903
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Melbourne, Australia
View Trial DetailsNCT06033027
Nervous System Diseases, Neurologic Disorder
Enschede, Overijssel, Netherlands
View Trial Details